The PARAGON‐HF study 46 compared the efficacy of ARNI and valsartan in patients with HFpEF aged over 50 years; ARNI therapy showed a trend of reducing the risk of primary outcomes and the HF readmission rate but had no obvious benefits for the risk of cardiovascular death.
← all excerpts
Chinese expert consensus on the diagnosis and treatment of chronic heart failure in elderly patients (2021).
1
—
—